AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Hodgkin’s Lymphoma Drugs Market Outlook, 2019 to 2023 - Bristol-Myers Squibb Company, Merck & Co, Ono Pharmaceutical Co, Pfizer, and Seattle Genetics are Dominating - ResearchAndMarkets.com

March 21, 2019

DUBLIN--(BUSINESS WIRE)--Mar 21, 2019--The “Global Hodgkin’s Lymphoma Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The hodgkin’s lymphoma drugs market will register a CAGR of close to 16% by 2023.

Hodgkin’s lymphoma is one of the most curable forms of lymphoma, with a patient survival rate of more than five years. The high unmet need for novel and innovative alternative treatment approaches. In addition, the introduction of target molecular hallmarks of this disease, including the aberrant phenotype of cancer cells, deregulated cancer pathways, and immune escape mechanisms.

With an increased understanding of the fundamental biology of Hodgkin’s lymphoma, companies have been able to develop drugs that are effective in treating the disease. This is expected to drive the market growth during the forecast period.

Development of novel pipeline drugs

The increase in the prevalence of Hodgkin’s lymphoma has led to a high unmet need for a strong pipeline of disease-modifying drugs. R&D activities are resulting in the availability of new drugs for the treatment of Hodgkin’s lymphoma.

Treatment of Hodgkin’s lymphoma patients with conjoint conditions

The treatment of Hodgkin’s lymphoma has generally been successful and well-tolerated by patients. However, there are challenges associated with the treatment of patients that have Hodgkin’s lymphoma with conjoint conditions, such as cardiac diseases, HIV infection, and pregnancy.

Hodgkin’s lymphoma is more common in patients with HIV. The presence of HIV in patients with Hodgkin’s lymphoma can have a negative impact on treatment tolerance and prognosis.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Key Players

  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Seattle Genetics Inc.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Comparison by type
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Seattle Genetics Inc.

For more information about this report visit https://www.researchandmarkets.com/research/3v3366/global_hodgkins?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190321005277/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Lymphoma Drugs

KEYWORD:

INDUSTRY KEYWORD: PROFESSIONAL SERVICES CONSULTING

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/21/2019 05:02 AM/DISC: 03/21/2019 05:02 AM

http://www.businesswire.com/news/home/20190321005277/en